GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Shares of Hims & Hers (HIMS) are down 92c, or 2%, to $45.09 in pre-market trading after GoodRx (GDRX) announced that all strengths of Ozempic and ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

Novo Nordisk's Wegovy® is one of two branded, FDA approved, GLP-1s. On February 21, 2025, the FDA determined that the semaglutide product shortage had been resolved.

According to the complaints, Hims & Hers was engaged in what plaintiffs describe as the deceptive promotion and sale of unauthorized and knockoff versions of Wegovy®.

According to the complaints, Hims & Hers was engaged in what plaintiffs describe as the deceptive promotion and sale of unauthorized and knockoff versions of Wegovy®.

According to the complaints, Hims & Hers was engaged in what plaintiffs describe as the deceptive promotion and sale of unauthorized and knockoff versions of Wegovy®.

News GlobeNewswire Hims & Hers Health, Inc. (HIMS) Alleged “Deceptive” Marketing of Wegovy® Triggers Securities Class Actions – HIMS Investors with Losses Encouraged to Contact Hagens Berman ...

According to the complaints, Hims & Hers was engaged in what plaintiffs describe as the deceptive promotion and sale of unauthorized and knockoff versions of Wegovy®.